Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors Influencing Visual and Refractive Outcomes for Scleral-Sutured Intraocular Lenses.

Journal of vitreoretinal diseases·2026
Same author

Quality Improvement in Vitreoretinal Surgery: Single-Center Report on Utility of Routine Intravenous Fluids in Pars Plana Vitrectomy.

Journal of vitreoretinal diseases·2026
Same author

Machine Learning Approach to Predict Postoperative Pain and Opioid Usage in Elective Primary Spine Surgery: A Retrospective Study.

Journal of pain research·2026
Same author

Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

Outcomes and Complications of Pars Plana Vitrectomy for Nonclearing Vitreous Hemorrhage Without Tractional Elements.

Ophthalmology. Retina·2026
Same author

Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know.

Survey of ophthalmology·2026

Related Experiment Video

Updated: Mar 26, 2026

Methodology for Biomimetic Chemical Neuromodulation of Rat Retinas with the Neurotransmitter Glutamate In Vitro
12:56

Methodology for Biomimetic Chemical Neuromodulation of Rat Retinas with the Neurotransmitter Glutamate In Vitro

Published on: December 19, 2017

8.2K

Argus II retinal prosthesis system: An update.

Aleksandra V Rachitskaya1, Alex Yuan1

  • 1a Cole Eye Institute, Cleveland Clinic Foundation , Cleveland , Ohio , USA.

Ophthalmic Genetics
|February 9, 2016
PubMed
Summary
This summary is machine-generated.

The Argus II retinal prosthesis system offers hope for patients with retinitis pigmentosa. This review details the device, its studies, and future potential for vision restoration.

Keywords:
Argusretinal implantretinitis pigmentosa

More Related Videos

Techniques for Processing Eyes Implanted With a Retinal Prosthesis for Localized Histopathological Analysis
12:01

Techniques for Processing Eyes Implanted With a Retinal Prosthesis for Localized Histopathological Analysis

Published on: August 2, 2013

20.4K
Techniques for Processing Eyes Implanted with a Retinal Prosthesis for Localized Histopathological Analysis: Part 2 Epiretinal Implants with Retinal Tacks
10:00

Techniques for Processing Eyes Implanted with a Retinal Prosthesis for Localized Histopathological Analysis: Part 2 Epiretinal Implants with Retinal Tacks

Published on: February 14, 2015

12.8K

Related Experiment Videos

Last Updated: Mar 26, 2026

Methodology for Biomimetic Chemical Neuromodulation of Rat Retinas with the Neurotransmitter Glutamate In Vitro
12:56

Methodology for Biomimetic Chemical Neuromodulation of Rat Retinas with the Neurotransmitter Glutamate In Vitro

Published on: December 19, 2017

8.2K
Techniques for Processing Eyes Implanted With a Retinal Prosthesis for Localized Histopathological Analysis
12:01

Techniques for Processing Eyes Implanted With a Retinal Prosthesis for Localized Histopathological Analysis

Published on: August 2, 2013

20.4K
Techniques for Processing Eyes Implanted with a Retinal Prosthesis for Localized Histopathological Analysis: Part 2 Epiretinal Implants with Retinal Tacks
10:00

Techniques for Processing Eyes Implanted with a Retinal Prosthesis for Localized Histopathological Analysis: Part 2 Epiretinal Implants with Retinal Tacks

Published on: February 14, 2015

12.8K

Area of Science:

  • Ophthalmology
  • Biomedical Engineering
  • Neuroscience

Background:

  • Retinitis pigmentosa causes progressive vision loss.
  • Current treatments are limited for advanced stages.
  • The Argus II system aims to restore functional vision.

Purpose of the Study:

  • To review the Argus II retinal prosthesis system.
  • To describe its components and clinical studies.
  • To discuss future directions for retinal implants.

Main Methods:

  • Review of existing literature and clinical data.
  • Description of the Argus II system's technology.
  • Analysis of studies involving Argus II implantation.

Main Results:

  • The Argus II system received FDA humanitarian use approval in 2013.
  • Studies evaluated its safety and efficacy in patients with retinitis pigmentosa.
  • The device provides some visual perception to patients with no light perception.

Conclusions:

  • The Argus II represents a significant advancement in treating blindness.
  • Further research is needed to optimize retinal prosthesis technology.
  • Future directions include improved device design and patient selection.